Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus
致癌性风险评估支持达格列净（一种钠-葡萄糖协同转运蛋白2抑制剂）在治疗2型糖尿病方面的长期安全性。
期刊:Diabetes Therapy
影响因子:2.6
doi:10.1007/s13300-014-0053-3
Reilly, Timothy P; Graziano, Michael J; Janovitz, Evan B; Dorr, Thomas E; Fairchild, Craig; Lee, Francis; Chen, Jian; Wong, Tai; Whaley, Jean M; Tirmenstein, Mark
